Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/009197DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMRISING VERINURAD
WO 21.01.2021
Int.Class A61K 9/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
Appl.No PCT/EP2020/069941 Applicant ASTRAZENECA AB Inventor VON CORSWANT, Christian
Disclosed herein are pharmaceutical formulations comprising verinurad or a pharmaceutically acceptable salt thereof that are resistant to alcohol-induced dose dumping and may be used in therapeutic and/or prophylactic methods.
2.WO/2021/009212ANTIBACTERIAL QUINOLONE DERIVATIVES
WO 21.01.2021
Int.Class C07D 519/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
Appl.No PCT/EP2020/069978 Applicant IDORSIA PHARMACEUTICALS LTD Inventor RITZ, Daniel
The invention relates to compounds of Formula I which are useful as antibacterial agents in medicine.
3.WO/2021/009332METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON
WO 21.01.2021
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
Appl.No PCT/EP2020/070240 Applicant ENYO PHARMA Inventor VONDERSCHER, Jacky
The present invention relates to a method for decreasing adverse-effects of interferon and to new compositions and methods of treatment.
4.WO/2021/009362BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING
WO 21.01.2021
Int.Class A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Appl.No PCT/EP2020/070326 Applicant CTXT PTY LIMITED Inventor MORROW, Benjamin Joseph
A compound of formula (I); wherein: W is O or NH; A1 is CRA or N; A2 is CRB or N; A3 is CRC or N; A4 is CRD or N; where no more than two of A1, A2, A3, and A4 may be N; one or two of RA, RB, RC and RD, (if present) are selected from H, F, Cl, Br, Me, CF3, cyclopropyl, cyano, OMe, OEt, CH2OH, CH2OMe and OH; the remainder of R A, RB, RC and RD, (if present) are H; RN1 is H or Me; one of RC2 and RC3 is C(=O)NH2; the other is selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl; RC1 and RC4 are independently selected from H, Cl, F, Br, Me, OMe, OEt, cyano, CF3, CH2OH, CH2OMe, C2-4 alkenyl and C5heterocyclyl.
5.WO/2021/010937METHODS AND COMPOSITIONS FOR THE TREATMENT OF SICKLE CELL DISEASES AND THALASSEMIA
WO 21.01.2021
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
Appl.No PCT/US2019/000033 Applicant EMMAUS MEDICAL, INC. Inventor NIIHARA, Yutaka
The present invention is generally directed to methods and compositions for the treatment of sickle cell diseases and thalassemia. It is more particularly directed to compositions containing L-glutamine, an L-glutamine salt or an L-glutamine derivative and at least one other active ingredient and methods using such compositions. In one aspect, the present invention is directed to a composition for treating sickle cell disease or β-thalassemia. The composition comprises: at least one gram of L-glutamine, an L-glutamine salt or an L-glutamine derivative; and, at least one gram of one type of fiber.
6.WO/2021/011177ENTERIC PROTON PUMP INHIBITOR SOFTGEL CAPSULE
WO 21.01.2021
Int.Class A61J 3/07
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
3Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
07into the form of capsules or similar small containers for oral use
Appl.No PCT/US2020/040068 Applicant R.P. SCHERER TECHNOLOGIES, LLC Inventor AHMAD, Humera
Disclosed is an enteric softgel capsule composition comprising (a) a fill material comprising a proton pump inhibitor, and (b) an enteric shell composition. The enteric softgel composition being stable and exhibiting a target dissolution profile and softgel capsule rupture characteristics.
7.WO/2021/011327COMPOUND FOR TREATING CYSTIC FIBROSIS
WO 21.01.2021
Int.Class A61K 31/357
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
357having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Appl.No PCT/US2020/041490 Applicant ORPHOMED, INC. Inventor SINGH, Nikhilesh Nihala
Provided herein is a compound represented by Formula I: (I) or a pharmaceutically acceptable salt, hydrate, solvate or complex thereof. Also provided are pharmaceutical compositions comprising the compound noted above, in combination with a pharmaceutically acceptable excipient.
8.WO/2021/011432COMPOSITIONS AND METHODS FOR TREATING DEMENTIA WITH LEWY BODIES
WO 21.01.2021
Int.Class A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Appl.No PCT/US2020/041736 Applicant EIP PHARMA, INC. Inventor ALAM, John, Jahangir
The present invention provides methods and compositions for treatment of Dementia with Lewy Bodies.
9.WO/2021/011462METHODS FOR THE NON-TOXIC TREATMENT FOR OPIOID DRUG WITHDRAWAL COMBINING NORIBOGAINE AND CANNABINOIDS
WO 21.01.2021
Int.Class A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
Appl.No PCT/US2020/041789 Applicant DEMERX, INC. Inventor SIGEL, Philip
The present invention is directed to the treatment of chemical substance abuse and withdrawal symptoms, especially withdrawal symptoms associated with opioids, utilizing a combination of an effective amount of a cannabinoid, in particular, cannabidiol (CBD) and/or A9-tetrahydrocannabinol (THC) in combination with low dosage noribogaine or a derivative salt, solvate or ansolvate thereof to treat withdrawal symptoms, both acute and longer term. It has unexpectedly been discovered that the cannabinoids as described herein work in conjunction with noribogaine to synergistically ameliorate and/or attenuate chemical substance abuse, especially including opioid withdrawal symptoms, both acute and longer term symptoms, such that low dose noribogaine (often in daily dosages of 30 milligrams or less) may be favorably co-administered to a patient suffering from withdrawal symptoms, substantially shortening the QT interval of the patient and providing for a particularly safe and effective method to treat opioid withdrawal symptoms.
10.WO/2021/011492L-Y-METHYLENEGLUTAMINE COMPOUNDS AND METHODS OF USE
WO 21.01.2021
Int.Class C07C 237/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
02having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
04the carbon skeleton being acyclic and saturated
Appl.No PCT/US2020/041839 Applicant UNIVERSITY OF MISSISSIPPI Inventor LE, Hoang Van
Disclosed are substantially pure L-y-methyleneglutamine, L-y- methyleneglutamic acid, and/or amide derivatives, and methods of use thereof. In particular, the presently disclosed subject matter relates to L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives thereof, and methods of treating cancer. The method comprises administering one or more substantially pure L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives to a subject in need thereof.